Triple-negative Breast Cancer and Poly(ADP-ribose) Polymerase Inhibitors

Park, Youngjin; Moriyama, Ayako; Kitahara, Tomoaki; Yoshida, Yutaka; Urita, Tasuku; Kato, Ryoji

doi:10.2174/187152012800617759

Cited by 14 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Triple negative breast cancers account for ~20% of all breast cancers and are associated with an aggressive clinical picture (20, 25, 29). Due to lack of hormone receptor or HER-2 expression, and no other known target for tailored therapy, the only current treatment option is chemotherapy.…”

Section: Brcaness: Sporadic Triple Negative Breast Cancersmentioning

confidence: 99%

BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different

Burgess

Puhalla

2014

Front. Oncol.

View full text Add to dashboard Cite

No longer is histology solely predictive of cancer treatment and outcome. There is an increasing influence of tumor genomic characteristics on therapeutic options. Both breast and ovarian cancers are at higher risk of development in patients with BRCA 1/2-germline mutations. Recent data from The Cancer Genome Atlas and others have shown a number of genomic similarities between triple negative breast cancers (TNBCs) and ovarian cancers. Recently, poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in hereditary BRCA 1/2-mutated and sporadic breast and ovarian cancers. In this review, we will summarize the current literature regarding the genomic and phenotypic similarities between BRCA 1/2-mutation related cancers, sporadic TNBCs, and sporadic ovarian cancers. We will also review Phase I, II, and III data using PARP inhibitors for these malignancies and compare and contrast the results with respect to histology.

show abstract

Section: Brcaness: Sporadic Triple Negative Breast Cancersmentioning

confidence: 99%

BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different

Burgess

Puhalla

2014

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Bevacizumaban anti-vascular endothelial growth factor (VEGF) antibody inhibiting angiogenesiswas also utilized as part of personalized therapy in the metastatic setting [4]. PARP inhibitors are pharmacological inhibitors of poly-ADP ribose polymerase, an enzyme responsible for repairing single-stranded DNA breaks [18][19][20]; as they may be given in BRCA mutant cancer, the PARP inhibitor olaparib was included as fourth line therapy. Approximately 25-45% of TNBC express AR, which may be utilized as a therapeutic target, and it is associated with a better prognosis [4,16,21]; however, AR status was negative in our case.…”

Section: Discussionmentioning

confidence: 99%

Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review

et al. 2020

View full text Add to dashboard Cite

Background: Breast cancer is a global health problemit is the most common malignancy among women. Triple negative breast cancers (TNBC) account for 10-20% of female breast cancer. Most TNBC cases confer poor prognosis. Brain metastasis appears in more than 15% in the triple negative breast cancer population, which causes serious decrease in survival. Changes of immunophenotype are not uncommon in breast cancer, offering new therapeutic options in cases where targetable proteins or pathways are being identified. Case presentation: After five lines of chemotherapy and 82 months following the first diagnosis, our patient with brain metastatic triple negative breast cancer had human epidermal growth factor receptor 2 (HER2) genetic heterogeneity in the metastatic tissue sample interpreted as HER2 status conversion. After the removal of the metastasis, we started first line therapy for metastatic HER2 positive cancer with trastuzumab and paclitaxel. After the first cycle of trastuzumab, on day 8, she had a seizure, and neurosurgical examination showed an abscess-like lesion. The punctate proved to be sterile by microbiological and pathological examination, so we continued cytostatic therapy without the anti-HER2 antibody. 3 months later, we could not identify the previous abscess-like lesion in the control computer tomography (CT) scan, and our patient had no neurological deficits. Conclusion: We emphasize the importance of regular tissue confirmation of predictive markers in progressive tumorous disease even if our presented case is not unequivocally a "conversion case". Tumor subtype is determined according to algorithms and definitions published in guidelines, nevertheless, use of different guidelines may lead to controversial interpretation in cases where HER2 genetic heterogeneity is present. Furthermore, we suggest that seronegative, aseptic intracranial fluid effusion after the removal of a brain metastasis may possibly be a side effect of trastuzumab.

show abstract

“…miRNAs represent another type of molecular markers for diagnosis and targeted drug delivery [37]. It can also be found in a number of recent review articles [42][43][44][45]. Further studies indicate that many miRNAs play crucial roles in cellular plasticity during breast tumorigenesis and metastasis [38].…”

Section: Drugs Designed To Target Triple Recep-tor Negative Breast Tumentioning

confidence: 99%

Targeted Drug Delivery for Breast Cancer Treatment

Sha¹,

Ye²

2013

Recent Patents on Anti-Cancer Drug Discovery

View full text Add to dashboard Cite

Breast cancer is the commonest type of malignant tumor in women, comprising of about 30% of all cancers in women worldwide. In the past decades, the mortality of breast cancer patients has significantly been reduced due to the adoption of periodic breast cancer screening and the emergence of various treatments, such as radiotherapy, chemotherapy, and surgery. Currently, chemotherapy is one of the most effective treatments for breast cancer. Its side effects, however, pose a long-term challenge on a patient's health. Thus, it is highly desirable to develop new therapies that can specifically target carcinoma cells without damaging normal and healthy cells. Tremendous efforts have been made to develop targeted drug delivery systems for breast cancer treatment. In this review, we intend to systematically examine recent progresses made along these directions. We highlighted various delivery carriers designed for directing the diffusion of therapeutic agents inside tumors to kill or suppress breast cancer cells. These carriers include molecular-recognition-element modified anticancer agents, stem cells that have tropism to breast cancers, nanoparticle-based anticancer drugs, and anticancer peptides. In particular, we discussed recent patents on the new targeted therapeutic delivery systems, with an emphasis on triple-negative breast cancer therapies.

show abstract

Triple-negative Breast Cancer and Poly(ADP-ribose) Polymerase Inhibitors

Cited by 14 publications

References 0 publications

BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different

BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different

Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review

Targeted Drug Delivery for Breast Cancer Treatment

Contact Info

Product

Resources

About